Navigation Links
Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects

ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 /PRNewswire/ -- Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics' NextGENe software for next-generation sequencing projects performed at Ambry.


Anja Kammesheidt PhD, Ambry's CSO said, "Our team at Ambry has been providing genomics solutions on Illumina's® Genome Analyzer platform for 2 years now. In light of diversifying applications, increasing project sizes, and new genomes to be explored, having a proven and innovative partner for bioinformatics is key. While some of our clients are interested in performing their own analyses, others are asking for extended support. We have been impressed with SoftGenetics' software tools, as well as their approach to take care of the clients' needs which is very much in line with Ambry's philosophy. We are looking forward to working together to provide tailored services to our clients."

Jonathan Liu PhD, SoftGenetics VP Research and Development echoed Dr. Kammesheidt's thoughts and added that, "the SoftGenetics/Ambry partnership provides a new strategic alliance that will not only provide a single streamlined source for next-generation sequencing researchers, but will also provide SoftGenetics with a deepened vision of future researcher requirements, allowing NextGENe to remain at the forefront of next-generation sequencing software."

"This highly unique alliance," continued John Fosnacht, SoftGenetics VP Sales and Marketing, "provides researchers wishing to utilize the power of next-generation sequencing a distinctive value proposition by combining the technical quality of Ambry Genetics sequencing with the unique analysis capabilities of NextGENe without the heavy investment typically required in next-generation sequencing instrumentation and bioinformatics. We all believe this is a true win-win situation for everyone."

"Next-generation sequencing services are more valuable to any scientific researcher if you can offer a full menu for bioinformatics support," said Ardy Arianpour, Director of Business Development, Genomic Services at Ambry Genetics. "Ambry Genetics has now become the genomics community's one-stop service shop for next-generation sequencing services. We can handle large projects and we can offer the most robust data analysis through the exclusive alliance with SoftGenetics."

Ambry Genetics has been providing next generation sequencing services to pharmaceutical, biotech and academic clients for a wide range of applications including targeted resequencing through custom or exome sequence capture, transcriptome, ChIP and de novo sequencing. Ambry Genetics is focused on delivering the highest quality results with the most sensible workflows while maintaining cost effective contracts for the genomics community.

About Ambry Genetics

Ambry Genetics is both a clinical, CAP-accredited and CLIA-certified commercial laboratory as well as a genomics services laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit

About SoftGenetics

SoftGenetics, LLC, located in State College Pennsylvania specializes in the development of genetic analysis tools for both research and diagnostic applications. Hallmarks of SoftGenetics software tools are advanced technologies, providing exceptional accuracy, and sensitivity in an easy-to-use Windows® user interface.

Its NextGENe software provides biologists with an easy-to-use software analysis tool which improves Next Generation Sequencing accuracy in a complete, freestanding Windows® based program. NextGENe virtually eliminates bioinformatics requirements, utilizes low cost hardware, and is compatible with all major NGS systems

To learn more or to request a 30-day trial of the software, please visit:

SOURCE Ambry Genetics; SoftGenetics

SOURCE Ambry Genetics; SoftGenetics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
6. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
7. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
8. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
9. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
10. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
11. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
Post Your Comments:
(Date:10/12/2017)... Oct. 12, 2017   Divoti USA will ... to the standard of the latest FDA requirements, which stipulates new ... Anyone in need of Medical ID jewelry such as Medical ... are engraved in terms of the new FDA requirements ... Divoti offers this dark ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):